公开(公告)号：EP1647292A4

公开(公告)日：2011-02-23

申请号：EP04730727

申请日：2004-04-30

申请人： MORISHITA RYUICHI ,  ANGES MG INC ,  SHIMADZU CORP

发明人： MORISHITA RYUICHI ,  TOMITA NARUYA ,  KUNUGIZA YASUO ,  TANIYAMA YOSHIAKI ,  KOIKE HIROMI ,  UDAGAWA HARUHIDE ,  KIMURA TATSUO

IPC分类号： A61M5/30 ,  A61K38/18 ,  A61K48/00 ,  C12N15/00

CPC分类号： A61M5/30 ,  A61K38/1833 ,  A61K48/00

公开(公告)号：EP1739425A4

公开(公告)日：2008-05-21

申请号：EP05728425

申请日：2005-03-30

申请人： ANGES MG INC

发明人： SATO NAOYUKI ,  OKOCHI MASAYASU ,  TANIYAMA YOSHIAKI ,  OGIHARA TOSHIO ,  MORISHITA RYUICHI

IPC分类号： G01N33/50 ,  G01N33/15 ,  G01N33/68

CPC分类号： G01N33/6896 ,  G01N2333/4709 ,  G01N2500/00 ,  G01N2500/04 ,  G01N2800/2821 ,  G01N2800/2835

摘要： It is intended to provide a method of identifying a candidate for a drug which comprises measuring the concentration of a soluble peptide, oligopeptide, polypeptide or protein in an equilibrated state in a solvent in the presence of a test compound so that the peptide, oligopeptide, polypeptide or protein can be eliminated from a fibril or an aggregate. It is also intended to provide an elution promoter for eliminating a peptide, an oligopeptide, a polypeptide or a protein from a fibril or an aggregate which comprises a compound obtained by the above identification method as the active ingredient.

公开(公告)号：EP1488813A4

公开(公告)日：2005-04-06

申请号：EP02707127

申请日：2002-03-22

申请人： ANGES MG INC

发明人： MORISHITA RYUUICHI ,  TANIYAMA YOSHIAKI

IPC分类号： A61K9/00 ,  A61K48/00 ,  A61K47/42

CPC分类号： A61K9/0009

摘要： Compositions for delivering a biologically active drug into a specific site in vivo which comprise microbubble-containing microspheres originating in albumin containing perfluorocarbon. The biologically active drug is preferably at least one member selected from the group consisting of oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, oligonucleotide probes, nucleotide vectors, virus vectors and plasmids. In using these compositions, the specific site is exposed to ultrasonic wave so that the biologically active drug can be introduced into the specific site.

公开(公告)号：EP1671655A4

公开(公告)日：2009-08-12

申请号：EP04772726

申请日：2004-08-27

申请人： ANGES MG INC

发明人： KUNUGIZA YASUO ,  TOMITA NARUYA ,  YOSHIKAWA HIDEKI ,  TANIYAMA YOSHIAKI ,  TAMAI KATSUTO ,  MORISHITA RYUICHI

IPC分类号： A61K48/00 ,  A61K9/00 ,  A61K9/08 ,  A61K31/7088 ,  A61K38/16 ,  A61P17/00 ,  A61P17/02 ,  A61P17/06

CPC分类号： A61K9/0024 ,  A61K31/7088 ,  A61K48/0075

摘要： It is intended to provide a clinically useful therapeutic method for skin diseases, in particular, intractable skin diseases. More specifically speaking, a polynucleotide such as DNA, oligonucleotide, RNA, siRNA or antisense is injected around a skin disease (wound, skin ulcer, psoriasis, etc.) site or subcutaneously introduced in a single dose of 10 mug to 10 mg by using a needle free syringe whereby a liquid drug is injected by moving a piston with the use of a gas pressure or the elastic force of an elastic member.

公开(公告)号：EP1136083A4

公开(公告)日：2005-11-16

申请号：EP00964686

申请日：2000-10-05

申请人： ANGES MG INC

发明人： MORISHITA RYUICHI ,  TANIYAMA YOSHIAKI ,  OGIHARA TOSHIO

IPC分类号： A61K9/127 ,  A61K38/18 ,  A61K48/00 ,  A61P9/04 ,  A61P9/10 ,  A61K35/76 ,  A61K38/22

CPC分类号： A61K48/005 ,  A61K9/127 ,  A61K38/1833 ,  A61K48/00 ,  A61K48/0083

摘要： Noninvasive administration of HGF gene in the form of Sendai virus (HVJ)-liposome into injured myocardium under echography makes it possible to promote angiogenesis and inhibit fibrosis in the myocardial layer, thereby restoring heart functions.